CoinShares International Limited has been approved for listing on Nasdaq Stockholm
Wednesday, 7 December 2022 |SAINT HELIER, Jersey -Nasdaq Stockholm's listing committee has today approved CoinShares International Limited's ("CoinShares" or the "Company") application for admission of the Company's shares to trading on Nasdaq Stockholm's main market. The approval is conditional upon customary conditions being fulfilled, for example that a prospectus is approved by and registered with the Swedish Financial Supervisory Authority ("SFSA") (Sw. Finansinspektionen) and that the requirements on liquidity of the Company's shares are fulfilled. First day of trading on Nasdaq Stockholm is scheduled to 19 December 2022 and last day of trading on Nasdaq First North Growth Market is scheduled to 16 December 2022.
The Company listed on Nasdaq First North Growth Market in March 2021 under the ticker "CS" and since the listing, the Company has worked strategically to develop the organization and its internal processes to meet the enhanced requirements placed on companies listed on Nasdaq Stockholm. The Company's board of directors and executive committee believe that a listing of the Company's shares on Nasdaq Stockholm will bring, amongst others, the following benefits:
- by trading on the most senior marketplace in Sweden, enhance the regulatory profile, and thereby also the credibility, of the Group;
- increase the Group's presence in the wider digital asset community which can contribute to higher levels of engagement with the Group's products and services;
- increase awareness of the Group among analysts, prospective investors and the media;
- make the Company's shares more attractive as a means of payment in connection with potential acquisitions; and
- enabling investment in the Company's shares by institutional players who otherwise may be restricted to invest in companies that are listed on a MTF.
It is hoped that the above-mentioned benefits will contribute towards continued value creation for the Company's shareholders, and it is therefore the opinion of the board of directors and the executive committee team that a listing on Nasdaq Stockholm is in the interest of all shareholders of the Company.
There is no offering or issuance of new shares in connection with the Company's shares being admitted to trading on Nasdaq Stockholm. Shareholders of CoinShares do not need to take any action in connection with the change of listing venue. The shares will be traded under the same ticker (CS) and ISIN code (JE00BLD8Y945).
CoinShares will prepare a prospectus in connection with the admission to trading of the Company's shares on Nasdaq Stockholm. The prospectus is expected to be approved by the SFSA and published on CoinShares' website, https://coinshares.com/investor-relations/reports-portal/ on or about 14 December 2022.
Baker McKenzie is the Company's legal advisor in connection with the admission to trading of the Company's shares on Nasdaq Stockholm.
CoinShares is Europe's largest and longest standing digital asset investment firm, managing billions of dollars of assets on behalf of its client base. The Group is focused on expanding investor access to the digital asset ecosystem by pioneering new financial products and services that seek to provide trust and transparency when accessing this new asset class. CoinShares is publicly listed on the Nasdaq First North Growth Market under the ticker CS and the OTCQX under the ticker CNSRF.
For more information on CoinShares, please visit: https://coinshares.com
Company | +44 (0)1534 513 100 | firstname.lastname@example.org
Investor Relations | +44 (0)1534 513 100 | email@example.com
Certified Advisor – Mangold Fondkommission AB | +46 (0)8 503 015 50 | firstname.lastname@example.orgTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Placeringsf. Nykredit Invest (Kapitalforening) – estimerede udlodninger for 20238.12.2023 15:37:01 CET | pressemeddelelse
På baggrund af de skattepligtige indtægter for 2023 har Placeringsf. Nykredit Invest (Kapitalforening) nu estimeret følgende ureviderede udlodninger for foreningens afdelinger for 2023: AfdelingISINValutaUdbytte pr. andelDanske FokusaktierDK0060231777DKK12,90Kredit Fokus KLDK0061066842DKK0,00 Det bemærkes, at der alene er tale om estimerede udlodninger, hvorfor der vil kunne ske ændringer. Der gøres endvidere opmærksom på at fx handelsaktivitet mv. i den resterende del af året kan påvirke de estimerede udlodninger i såvel opadgående som nedadgående retning. Endelige estimerede udlodninger vil blive offentliggjort på Nasdaq Copenhagen A/S den 24. januar 2024 og forventes udbetalt til investorerne den 2. februar 2024. Eventuel henvendelse vedrørende denne meddelelse kan rettes til direktør Tage Fabrin-Brasted, tlf. 44 55 92 00. Med venlig hilsen Placeringsforeningen Nykredit Invest Tage Fabrin-Brasted, direktør Vedhæftet fil FB_Plac_NI_estimerede_udlodninger_8_12_2023
Storaktionærmeddelelse8.12.2023 15:25:58 CET | pressemeddelelse
Se vedhæftede Vedhæftet fil Selskabsmeddelelse 32_2023 Storaktionærmeddelelse_NCI
Investeringsforeningen Investin – estimerede udlodninger for 20238.12.2023 15:23:20 CET | pressemeddelelse
På baggrund af de skattepligtige indtægter for 2023 har Investeringsforeningen Investin nu estimeret følgende ureviderede udlodninger for foreningens afdelinger for 2023: AfdelingISINValutaUdbytte pr. andelEMD Local CurrencyDK0060542504DKK0,00Sampension Globale Aktier KLDK0061074861DKK3,10Sampension Obligationer KLDK0061076213DKK0,00I&T Nordiske Aktier Large CapDK0061276656DKK0,00I&T Globale Aktier ESG SelectDK0061276573DKK5,80 Det bemærkes, at der alene er tale om estimerede udlodninger, hvorfor der vil kunne ske ændringer. Der gøres endvidere opmærksom på at fx handelsaktivitet mv. i den resterende del af året kan påvirke de estimerede udlodninger i såvel opadgående som nedadgående retning. Endelige estimerede udlodninger vil blive offentliggjort på Nasdaq Copenhagen A/S den 16. januar 2024 og forventes udbetalt til investorerne den 25. januar 2024. Eventuel henvendelse vedrørende denne meddelelse kan rettes til direktør Tage Fabrin-Brasted, tlf. 44 55 92 00. Med venlig hilsen Invest
Storaktionærmeddelelse8.12.2023 15:20:16 CET | pressemeddelelse
Se vedhæftede Vedhæftet fil Selskabsmeddelelse 31_2023 Storaktionærmeddelelse_MHI
Latest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broad population of patients with early breast cancer; supports regulatory submissions8.12.2023 15:15:00 CET | Press release
With 5.6 months of additional follow-up and 78.3% of patients having completed Kisqali® (ribociclib) investigational treatment, the updated analysis shows sustained iDFS benefitand stability in secondary endpoints including overall survival (OS)1,2 iDFS benefit remains consistent across key patient subgroups; among patients with stage II and stage III tumors, Kisqali lowered risk by 30% and 24.5%, respectively1,2 Latest analysis continues to show a well-tolerated safety profile in line with previously reported results, and quality of life for Kisqali patients preserved vs. endocrine therapy (ET) alone1,2,3 Risk of recurrence remains a short and long term concern; one in eight women treated with ET alone in NATALEE likely to experience invasive disease at 3 years1,2 Kisqali is currently approved in the metastatic setting, where it has consistently demonstrated statistically significant OS benefit across three Phase III trials4-15;Novartis has filed NATALEE results with EMA and will subm